Maze Therapeutics, Inc. (NASDAQ: MAZE)

Sector: Healthcare Industry: Biotechnology CIK: 0001842295
P/B 2.23
P/E -8.36
P/S 0.00
Market Cap 847.88 Mn
ROIC (Qtr) -38.96
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 24.18 Mn
Debt/Equity (Qtr) 0.06

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 317.86M provide 66.72x coverage of short-term debt 4.76M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 422.06M provides 17.45x coverage of total debt 24.18M, indicating robust asset backing and low credit risk.
  • Tangible assets of 422.06M provide robust 29.25x coverage of other current liabilities 14.43M, indicating strong asset backing.
  • Short-term investments of 67.16M provide solid 4.65x coverage of other current liabilities 14.43M, indicating strong liquidity.
  • Cash reserves of 317.86M provide robust 14.38x coverage of current liabilities 22.11M, indicating strong short-term solvency.

Cons

  • Investment activities of (68.18M) provide weak support for R&D spending of 103.09M, which is -0.66x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (106.66M) shows concerning coverage of stock compensation expenses of 13.18M, with a -8.09 ratio indicating potential earnings quality issues.
  • Free cash flow of (108.03M) provides weak coverage of capital expenditures of 1.36M, with a -79.14 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (126.41M) show weak coverage of depreciation charges of 5.68M, with a -22.26 ratio indicating high capital intensity and potential reinvestment needs.
  • Retained earnings of (454.98M) provide limited buffer against comprehensive income items of 69000, which is -6593.90x, indicating elevated exposure to market risks.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 1.44 12.31
EV to Cash from Ops. -5.69 23.25
EV to Debt 25.11 738.44
EV to EBIT -4.80 -9.16
EV to EBITDA -4.71 6.95
EV to Free Cash Flow [EV/FCF] -5.62 21.90
EV to Market Cap 0.72 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 2.23 22.34
Price to Earnings [P/E] -8.36 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 4.11 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -136.98 -27.13
Cash and Equivalents Growth (1y) % 110.93 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -328.36 -46.93
EBITDA Growth (1y) % -282.40 -1.68
EBIT Growth (1y) % -323.02 -56.45
EBT Growth (1y) % -323.02 -12.70
EPS Growth (1y) % 84.35 -28.31
FCF Growth (1y) % -239.95 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 14.38 3.85
Current Ratio 17.70 7.27
Debt to Equity Ratio 0.06 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22